Share page on LinkedIn

Financial Times Global Pharmaceutical and Biotechnology Conference

7 - 9 November, 2022, In-person and Online event

Driving Investment and Innovation in Life Sciences

The Global Pharmaceutical and Biotechnology Conference is the essential annual event to stay up to date with innovation and growth across the sector. Leaders in life sciences from around the world will convene in London to discuss the latest trends in areas such as drug discovery, clinical trials and market access, exploring new frontiers for business and for healthcare.

25% discount

As a lead sponsor, ICON is pleased to offer senior executives at clients and other third parties, a 25% discount for this in-person and online event supported by the world's best journalism. Simply complete the short form and we will contact you.

In-person pass   Digital pass
  • Get access to in-person sessions and networking.
  • Network and connect with your peers.
  • Super Early Bird rate of £2,199 / €2,607
  • With ICON discount code: £1,649 / €1,955
  • Access to the live stream, Q&A and video on demand.
  • Super Early Bird rate of £149 / €176
  • With ICON discount code: £112 / €132


Featured speakers include:

Steve Cutler, CEO, ICON plc

Dave Ricks, Chair and CEO, Eli Lilly

Richard Saynor, CEO, Sandoz

Christophe Weber, President and CEO, Takeda

David Loew, CEO, Ipsen

Padraic Ward, Head of Pharma International, Roche

Stefan Oelrich, President, Bayer Pharmaceuticals

Amanda Pritchard, Chief Executive, NHS England

ICON speakers:

Steve Cutler

Steve Cutler


7 November 2022 - 11:55 AM - 12:10 PM GMT

Interview: More than a year after acquiring another large CRO and driving a successful integration strategy, hear how one company has enhanced its value proposition and its role in a rapidly shifting the clinical trials landscape in which the future could be many more trials delivered in shorter timeframes, but conversely of greater operational and scientific complexity.

Harpeet Gill

Harpreet Gill

VP, Decentralised Trials, ICON

  • Panel: Drug development - Digitising, decentralising and accelerating R&D
  • 9 November, 12:00 PM - 12:45 PM GMT
    • What progress is being made in virtualised R&D models and how reliable are they?
    • What are some of the challenges in ensuring the integrity of decentralised clinical trials?
    • Is the average cost and time it takes to develop a drug really going down because of digital transformation and decentralisation?
    • What are the pros and cons of small vs. mass population drug development strategies?

Other panelists include:

  • Sastry Chilukuri, Co-CEO, Medidata
  • Colin Terry, Partner, Life Sciences Consulting, Deloitte
  • Moderator: Financial Times journalist TBD